BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Theravance Biopharma (TBPH)Theravance BiopharmaEarnings

DUBLIN , Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm

Related news

TBPHTheravance Biopharma2025-11-10 21:05 EST

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-08-10 12:30 EST

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

VERUVeru Inc2026-08-03 12:30 EST

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

LUNGPulmonx2026-04-15 20:05 EST

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

XAIRBeyond Air2026-01-26 21:05 EST

Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

INSMInsmed2026-07-23 11:00 EST

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

XAIRBeyond Air2026-02-13 12:30 EST

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

RVPHReviva Pharmaceuticals2025-11-13 21:05 EST

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-08-10 12:30 EST

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Stock data

Close
17.01 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States